<DOC>
	<DOC>NCT00552344</DOC>
	<brief_summary>The primary objective of the study is to assess the safety of long term therapy with Certolizumab Pegol in those subjects participating in study C87085 [NCT00552058].</brief_summary>
	<brief_title>A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease</brief_title>
	<detailed_description>This study consisted of: - Induction Period (dosing at Weeks 0, 2, and 4) - Maintenance Dosing (dosing every 4 weeks up to Week 260) - End of Treatment Visit that occurred at Week 262/Withdrawal Visit and a Safety Follow-up Visit (SFU; 12 weeks after final dose)</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Subject participated in study C87085 [NCT00552058] in which the subject completed the study at Week 6 Subject is capable of providing informed consent, which must be obtained prior to any study related procedures Have a chest Xray taken at Visit 1 that is read by a qualified radiologist or pulmonary physician, with no evidence of current active Tuberculosis (TB) or old inactive TB Subject has taken a TB survey and is committed to comply with TB prophylaxis if applicable Subject is experiencing an ongoing serious adverse event assessed as being related to study medication or is experiencing a serious adverse event that is still not assessable Subject has an intercurrent illness that requires termination of treatment, such as a serious infection (e.g. TB, pneumonia, sepsis, pyelonephritis, fistula abscess) Subject is noncompliant with TB prophylactic treatment (if applicable) Subject has had a chest Xray at Visit 1 that shows an abnormality suggestive of a malignancy or active infection, including TB Female who is pregnant or breast feeding Female of child bearing age or post puberty males not practicing effective birth control Subject is expecting to receive any live virus or bacterial vaccination within 3 months of first Study Medication administration, during the trial or 3 months after last dose of study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>CDP 870</keyword>
	<keyword>Certolizumab Pegol</keyword>
	<keyword>CIMZIA</keyword>
	<keyword>Crohn's Disease</keyword>
	<keyword>Crohn Disease</keyword>
	<keyword>CD Induction</keyword>
	<keyword>Induction</keyword>
	<keyword>Clinical response</keyword>
	<keyword>Clinical remission</keyword>
</DOC>